Abstract https://bit.ly/49t5nkW. Go to full publication
Clinical comorbidity phenotypes in COPD and their biomarker signatures.
September 1, 2026
ERJ Open Res
- Home
-
Publications
Publications
Active filters
Add filters (0)
921 results
Investigation of non-invasive tests for fibrosis diagnosis and prognostication of events in metabolic dysfunction-associated steatotic liver disease: A prospective study cohort.
September 1, 2026
Ann Hepatol
Abstract INTRODUCTION AND OBJECTIVES Risk stratification is important in the management of metabolic dysfunction-associated steatotic liver disease (MASLD) to prioritize monitoring and treatment resources. We evaluated whether non-invasive tests (NITs) can predict major adverse liver outcomes (MALOs) and diagnose advanced fibrosis in patients with MASLD. PATIENTS AND METHODS A prospective cohort of 270 patients with […]
Endotrophin Measured by PRO-C6 as a Prognostic Biomarker for Liver-Related Events in Patients With Advanced Chronic Liver Disease.
September 1, 2026
Liver Int
Abstract BACKGROUND & AIMS Prognostic non-invasive tests for liver-related events in compensated cirrhosis are needed. Endotrophin, a fragment of type VI alpha 3 collagen involved in fibrosis and inflammation, has been associated with adverse outcomes in several chronic diseases. This study examined the association between baseline endotrophin levels, measured by nordicPRO-C6 (PRO-C6), and liver-related events […]
Basement membrane remodeling biomarkers are modulated and reflect treatment response to JAK inhibitors in patients with atopic dermatitis – results from two longitudinal clinical studies.
August 18, 2026
J Invest Dermatol
Go to full publication
Combination therapy of RAS inhibition and glucagon-like peptide-1 receptor agonist improves a marker of kidney fibrosis in people with type 2 diabetes.
August 17, 2026
Am J Physiol Cell Physiol
Abstract In type 2 diabetes (T2D), kidney fibrosis drives the progression of chronic kidney disease (CKD) and kidney failure. Lower urinary levels of collagen type III degradation (C3M), a biomarker of extracellular matrix (ECM) turnover, have been associated with CKD progression. We investigated the effect of combination therapy with renin-angiotensin system inhibition (RASi) and glucagon-like […]
Collagen Turnover Is Associated with Disease Severity, Bone Marrow Fibrosis, and the JAK2V617F Variant Allele Frequency in Myeloproliferative Neoplasms.
August 6, 2026
Cancers (Basel)
Abstract : Myeloproliferative neoplasms (MPNs) are blood cancers characterized by elevated blood cell counts, bone marrow fibrosis (BMF), and chronic inflammation, which drives disease progression. BMF results from disrupted collagen turnover in the bone marrow extracellular matrix (ECM), making its reduction or stabilization a key therapeutic goal. Non-invasive biomarkers reflecting collagen turnover could potentially improve […]
Serological biomarkers of extracellular matrix proteins are associated with hidradenitis suppurativa disease severity and treatment response.
August 1, 2026
Skin Health Dis
Abstract Chronic inflammation in hidradenitis suppurativa (HS) disrupts tissue architecture and basement membrane integrity. Biomarkers of extracellular matrix (ECM) and basement membrane degradation (BGM, C7M, C4M) increase with disease severity, while NIC (linker protein degradation) decreases. Elevated baseline C7M is significantly associated with greater improvement in IHS4 following TNF-α inhibitor therapy. ECM remodelling biomarkers reflect […]
Prospective validation of imaging and serum diagnostic biomarkers of steatohepatitis and fibrosis in MASLD: the LITMUS Imaging Study.
August 1, 2026
Nat Med
Abstract There is a need for robust evaluations of noninvasive biomarkers for metabolic dysfunction-associated steatotic liver disease. This prospective multicenter study assessed the diagnostic accuracy of imaging (including liver stiffness measurement (LSM) using magnetic resonance elastography (MRE) and FibroScan (vibration-controlled transient elastography (VCTE)), serum biomarkers (including NIS2+) and composite scores (including Agile 3+ and Agile […]
Crosslinked Fibrin Fragment (X-FIB) as a Biomarker for Endotype Differentiation and Response to Omalizumab Treatment in Chronic Spontaneous Urticaria.
August 1, 2026
Allergy
Go to full publication
A framework and shared vocabulary to identify actionable protein biomarkers and enable optimal precision medicine: Myth-Busting with Unicorn Biomarkers.
July 25, 2026
J Hepatol
Abstract Not all biomarkers are equal, and some should not be termed biomarkers. Despite an explosion in putative biomarker discoveries from high-throughput proteomic technologies, very few advance beyond initial excitement to become validated, clinically actionable tools. Most stall in a “biomarker valley of death,” where promising signals fail to meet robust technical, scientific, and regulatory […]
